The MATRIX study: evaluating the data in older adults

Abstract

In summary, the MATRIX study evaluated the use of OXY-TDS in older adults residing in community settings. Although it was a community-based study, a large segment of those studied had traits similar to those residing in long-term care settings--699 patients were aged 75 years or older; many had comorbid diseases; and many had a long history of OAB. MATRIX found that the transdermal form of oxybutynin was a safe and effective method to manage OAB in this older population. Adverse events reported were minor and local, with the most common event being local skin irritation. The transdermal formulation improved the symptoms associated with OAB and improved QOL. Although nursing home residents were not studied in MATRIX, it appears that the transdermal formulation of oxybutynin would be an agent of choice in older adults.